RESUMEN

OBJECTIVE: To investigate clinical effects of hepatic artery interventional embolization chemotherapy (TACE) for primary hepatocellular carcinoma (PHC). METHODS: 73 patients with PHC in our hospital from January 2017 to January 2018 were selected and divided into 37 cases in study group and 36 cases in control group by random number table method. The control group received only ultrasound-guided microwave ablation treatment, and the study group received TACE treatment again before surgery based on control group. The expression levels of cancer antigen 125 (CA125), alpha-fetoprotein (AFP), multiple tumor suppressors 1 (P16) proteins, and cancer antigen 19-9 (CA19-9) were compared between the two groups at different time periods after treatment, and the remission rate (ORR), control rate (DCR), complication rate at 3 months after treatment and survival rate at 3 years after treatment were compared. RESULTS: After 1 year of treatment, ORR, DCR, and P16 protein levels in the study group were higher than those in the control group (P < 0.05), and differences were statistically significant; CA125, CA19-9, and AFP levels in study group were lower than those in the control group (P < 0.05), and differences were statistically significant. The regression equation showed that long-term survival rate of both groups showed decreasing trend over time, while long-term survival rate of study group was always higher than that of the control group. CONCLUSION: Comprehensive intervention for hepatic artery interventional chemoembolization in patients with primary hepatocellular carcinoma is more effective, which can effectively reduce incidence of complications and adverse effects in patients and help shorten treatment time of hepatic artery interventional chemoembolization in patients.

RESUMEN

With the increasing importance of environmental and economic sustainability concerns, the concept of Environmental, Social, and Governance (ESG) has gained significant attention. In the era of digitalization, a research approach called carbon sentiment analysis has emerged as an innovative method. This study aims to explore the connections between carbon sentiment, ESG, and corporate sustainable growth within the context of the green economy. By using Ordinary Least Squares (OLS) regression analysis and establishing a panel data model of ESG performance and sustainable growth for Chinese listed companies, a notable positive correlation between the two variables was observed. Endogeneity was addressed using the two-stage instrumental variable method (2SLS) and the dynamic panel Generalized Method of Moments (GMM) model, with the results remaining robust both before and after the COVID-19 pandemic. Carbon-related news and textual information were collected and analyzed using advanced deep learning methods in Natural Language Processing (NLP), specifically Bidirectional Encoder Representations from Transformers (BERT) and Long Short-Term Memory (LSTM) models. This analysis enabled sentiment analysis and identification of the sentiment orientation of carbon news. The obtained sentiment scores were then integrated with company data to establish a moderation effect model. The findings of the study reveal that carbon sentiment significantly and positively moderates ESG performance in relation to corporate sustainable growth. Furthermore, the construction of a mediation effect model showed that carbon sentiment can moderate ESG performance by reducing environmental uncertainty, enhancing social trust, and alleviating financing constraints, thereby influencing corporate sustainable growth. The results of the heterogeneity group regression analysis demonstrate that the impact of ESG performance driven by carbon sentiment on sustainable growth is more pronounced in carbon market pilot regions, non-heavily polluting industries, and labor-intensive industries. This research provides a fresh perspective for understanding the dynamics of ESG, online carbon sentiment, and their implications for corporate sustainable growth. Additionally, it contributes to the development of the green economy and the formulation of environmental management policies.

Asunto(s)

RESUMEN

Random skin flap grafting is the most common skin grafting technique in reconstructive surgery. Despite progress in techniques, the incidence of distal flap necrosis still exceeds 3%, which limits its use in clinical practice. Current methods for treating distal flap necrosis are still lacking. Pinocembrin (Pino) can inhibit reactive oxygen species (ROS) and cell death in a variety of diseases, such as cardiovascular diseases, but the role of Pino in random flaps has not been explored. Therefore, we explore how Pino can enhance flap survival and its specific upstream mechanisms via macroscopic examination, Doppler, immunohistochemistry, and western blot. The results suggested that Pino can enhance the viability of random flaps by inhibiting ROS, pyroptosis and apoptosis. The above effects were reversed by co-administration of Pino with adeno-associated virus-silencing information regulator 2 homolog 3 (SIRT3) shRNA, proving the beneficial effect of Pino on the flaps relied on SIRT3. In addition, we also found that Pino up-regulates SIRT3 expression by activating the AMP-activated protein kinase (AMPK) pathway. This study proved that Pino can improve random flap viability by eliminating ROS, and ROS-induced cell death through the activation of SIRT3, which are triggered by the AMPK/PGC-1α signaling pathway.

Asunto(s)

RESUMEN

PURPOSE: Although existing evidence from clinical trials has demonstrated manifestation of gastrointestinal perforation with the use of ramucirumab, overall risks have yet to be reported. Therefore, we performed a meta-analysis of published randomized controlled trials (RCTs) to get a better understanding of the overall incidence and risk of gastrointestinal perforation associated with ramucirumab. METHODS: The PubMed and Web of Science databases as well as abstracts presented at American Society of Clinical Oncology conferences were searched to identify relevant studies published up to 01 May 2015. Eligible studies included randomized trials of ramucirumab either alone or in combination with another agent compared with the control arm without ramucirumab and that reported gastrointestinal perforation event. Overall incidence, relative risk (RR) and 95% confidence intervals (CI) were computed using fixed- or random-effects models depending on the heterogeneity of the included studies. RESULTS: A total of 4579 patients with a variety of solid malignancies from six RCTs were included in our meta-analysis. The incidence of gastrointestinal perforation related to ramucirumab was 1.5% (95% CI 1.1-2.1%) with a mortality of 29.8% (95% CI 14.9-50.7%). The RR of gastrointestinal perforation associated with ramucirumab was 2.56 (95% CI 1.29-5.09; P = 0.007). CONCLUSIONS: Treatment with the ramucirumab is associated with a significant increase in risk of gastrointestinal perforation in cancer patients.

Asunto(s)